Skip to main content
SpringerLink
Log in

Alcohol and Drug Use Disorders

  • Chapter
  • First Online:
Chronic Illness Care

  • 700 Accesses

Abstract

Alcohol and drug use exist on a spectrum ranging from occasional use without consequences to a devastating chronic illness. A history of systemic inequities and racism has contributed to poorer outcomes regarding substance use, treatment, and consequences among minoritized groups. Substance use disorders may exist on their own, exacerbate chronic conditions, or cause other chronic illnesses. Addiction stigma remains a barrier to care for patients including lack of access to treatment, particularly in rural settings. Use of non-stigmatizing, person-first language can improve quality of care and should be emphasized in all healthcare settings. Screening for unhealthy alcohol and drug use is part of obtaining a comprehensive medical history and has implications for the diagnosis and management of numerous medical and psychiatric conditions. Effective, comprehensive substance use disorder treatment plans include pharmacotherapy, behavioral interventions, and recovery support. Medications should not be withheld from those not engaging in counseling. Telehealth promotes engagement and increases access to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Latine(s) (Lah-tEENn-eh) is a pan-ethnic, gender-inclusive form of the word Latino(s). Rather than Latinx, which is not congruent with Spanish orthography, Latine replaces the gendered o/a with an e, already in use in some Spanish words (e.g., estudiante.). It is best practice to ask patients about their preferences regarding these terms.

References

  1. Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021.

    Google Scholar 

  2. Grossman ER, Benjamin-Neelon SE, Sonnenschein S. Alcohol consumption during the COVID-19 pandemic: a cross-sectional survey of US adults. Int J Environ Res Public Health. 2020;17(24):9189. Published 2020 Dec 9. https://doi.org/10.3390/ijerph17249189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for health. Statistics. 2021; (CDC)

    Google Scholar 

  4. U.S. Department of Health and Human Services (HHS), Office of the Surgeon General. Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health. Washington, DC: HHS; 2016.

    Google Scholar 

  5. NIDA. Is drug addiction treatment worth its cost?; 2020, June 3. https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/frequently-asked-questions/drug-addiction-treatment-worth-its-cost. Accessed 16 Dec 2021.

  6. Miller T, Hendrie D. Substance abuse prevention dollars and cents: a cost-benefit analysis, DHHS Pub. No. (SMA) 07-4298. Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration: Rockville, MD; 2008.

    Google Scholar 

  7. Jordan A, Mathis M, Haeny A, Funaro M, Paltin D, Ransome Y. An evaluation of opioid use in black communities: a rapid review of the literature. Harv Rev Psychiatry. 2021;29(2):108–30. https://doi.org/10.1097/HRP.0000000000000285.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lopez-Vergara HI, Yang M, Weiss NH, Stamates AL, Spillane NS, Feldstein Ewing SW. The cultural equivalence of measurement in substance use research. Exp Clin Psychopharmacol. 2021;29(5):456–65. https://doi.org/10.1037/pha0000512.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Netherland J, Hansen H. White opioids: pharmaceutical race and the war on drugs that wasn’t. BioSocieties. 2017;12(2):217–38. https://doi.org/10.1057/biosoc.2015.46.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pinedo M. A current re-examination of racial/ethnic disparities in the use of substance abuse treatment: do disparities persist? Drug Alcohol Depend. 2019;202:162–7. https://doi.org/10.1016/j.drugalcdep.2019.05.017.

    Article  PubMed  Google Scholar 

  11. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed., American Psychiatric Association; 2013.

    Google Scholar 

  12. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1–2):120–30. https://doi.org/10.1016/j.drugalcdep.2010.11.004. Epub 2010 Dec 8.

    Article  PubMed  Google Scholar 

  13. Center for Behavioral Health Statistics and Quality. Results from the 2017 National Survey on drug use and health: detailed tables. Substance Abuse and Mental Health Services Administration; 2018. Accessed 24 Dec 2021.

    Google Scholar 

  14. Harrington M, Robinson J, Bolton SL, Sareen J, Bolton J. A longitudinal study of risk factors for incident drug use in adults: findings from a representative sample of the US population. Can J Psychiatr. 2011;56(11):686–95. https://doi.org/10.1177/070674371105601107.

    Article  Google Scholar 

  15. LeTendre ML, Reed MB. The effect of adverse childhood experience on clinical diagnosis of a substance use disorder: results of a nationally representative study. Subst Use Misuse. 2017;52(6):689–97. https://doi.org/10.1080/10826084.2016.1253746. December 24, 2021, 4:51 PM.

  16. Schmaling KB, Blume AW, Skewes MC. Negative life events and incident alcohol use disorders among ethnic minorities. J Ethn Subst Abus. 2020;19(2):327–42. https://doi.org/10.1080/15332640.2018.1548322.

    Article  Google Scholar 

  17. Sheu R, Lussier D, Rosenblum A, et al. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med. 2008;9(7):911–7.

    Article  PubMed  Google Scholar 

  18. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–9. https://doi.org/10.2174/1874473711104040241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rezkalla SH, Kloner RA. Cocaine-induced acute myocardial infarction. Clin Med Res. 2007;5(3):172–6. https://doi.org/10.3121/cmr.2007.759.

    Article  PubMed  PubMed Central  Google Scholar 

  20. NIDA. Part 1: the connection between substance use disorders and mental illness. National Institute on Drug Abuse website; 2021. https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness. Accessed 6 Nov 2021.

    Google Scholar 

  21. Iqbal MN, Levin CJ, Levin FR. Treatment for substance use disorder with co-occurring mental illness. Focus (American Psychiatric Publishing). 2019;17(2):88–97. https://doi.org/10.1176/appi.focus.20180042.

    Article  PubMed  Google Scholar 

  22. McHugh RK, Votaw VR, Fulciniti F, et al. Perceived barriers to smoking cessation among adults with substance use disorders. J Subst Abus Treat. 2017;74:48–53. https://doi.org/10.1016/j.jsat.2016.12.008.

    Article  Google Scholar 

  23. O’Connor EA, Perdue LA, Senger CA, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320(18):1910–28. https://doi.org/10.1001/jama.2018.12086.

    Article  PubMed  Google Scholar 

  24. Patnode CD, Perdue LA, Rushkin M, et al. Screening for unhealthy drug use: updated evidence report and systematic review for the US preventive services task force. JAMA. 2020;323(22):2310–28. https://doi.org/10.1001/jama.2019.21381.

    Article  PubMed  Google Scholar 

  25. Hagan JF, Shaw JS, Duncan P, editors. Bright futures: guidelines for health supervision of infants, children, and adolescents. 4th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2017.

    Google Scholar 

  26. Price HR, Collier AC, Wright TE. Screening pregnant women and their neonates for illicit drug use: consideration of the integrated technical, medical, ethical, legal, and social issues. Front Pharmacol. 2018:9. https://www.frontiersin.org/article/10.3389/fphar.2018.00961. Accessed 20 Jan 2022.

  27. Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness. Am J Prev Med. 2008;34(2):143–52. https://doi.org/10.1016/j.amepre.2007.09.035.

    Article  PubMed  Google Scholar 

  28. Denny CH, Hungerford DW, McKnight-Eily LR, et al. Self-reported prevalence of alcohol screening among U.S. adults. Am J Prev Med. 2016;50:380–3.

    Article  PubMed  Google Scholar 

  29. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Burns E, Gray R, Smith LA. Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction. 2010;105(4):601–14. https://doi.org/10.1111/j.1360-0443.2009.02842.x.

    Article  PubMed  Google Scholar 

  31. Campbell CE, Maisto SA. Validity of the AUDIT-C screen for at-risk drinking among students utilizing university primary care. J Am Coll Heal. 2018;66(8):774–82. https://doi.org/10.1080/07448481.2018.1453514.

    Article  Google Scholar 

  32. Crawford EF, Fulton JJ, Swinkels CM, Beckham JC, Calhoun PS. Diagnostic efficiency of the AUDIT-C in U.S. veterans with military service since September 11, 2001. Drug Alcohol Depend. 2013;132(1):101–6. https://doi.org/10.1016/j.drugalcdep.2013.01.012.

    Article  PubMed  Google Scholar 

  33. Samet JH, O’Connor PG. Alcohol abusers in primary care: readiness to change behavior. Am J Med. 1998;105(4):302–6.

    Article  CAS  PubMed  Google Scholar 

  34. Frank D, DeBenedetti AF, Volk RJ, Williams EC, Kivlahan DR, Bradley KA. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups. J Gen Intern Med. 2008;23(6):781–7. https://doi.org/10.1007/s11606-008-0594-0.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Saitz R, Lepore MF, Sullivan LM, Amaro H, Samet JH. Alcohol abuse and dependence in Latinos living in the United States: validation of the CAGE (4M) questions. Arch Intern Med. 1999;159(7):718–24. https://doi.org/10.1001/archinte.159.7.718.

    Article  CAS  PubMed  Google Scholar 

  36. Xuan B, Li P, Yang L, Li M, Zhou J. Similarities and differences in diagnostic scales. In: Zhang X, Shi J, Tao R, eds. Substance and non-substance addiction. Advances in experimental medicine and biology. Springer; 2017:133–168. doi:https://doi.org/10.1007/978-981-10-5562-1_8.

  37. McNeely J, Cleland CM, Strauss SM, Palamar JJ, Rotrosen J, Saitz R. Validation of self-administered single-item screening questions (SISQs) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med. 2015;30(12):1757–64. https://doi.org/10.1007/s11606-015-3391-6.

    Article  PubMed  PubMed Central  Google Scholar 

  38. McNeely J, Wu L, Subramanian G, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016;165(10):690–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abus Treat. 2007;32(2):189–98. https://doi.org/10.1016/j.jsat.2006.08.002.

    Article  Google Scholar 

  40. Gonzalez Suitt K, Castro Y, Caetano R, Field CA. Predictive utility of alcohol use disorder symptoms across race/ethnicity. J Subst Abus Treat. 2015;56:61–7. https://doi.org/10.1016/j.jsat.2015.03.001.

    Article  Google Scholar 

  41. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–51. https://doi.org/10.1176/appi.ajp.2013.12060782.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Forman RF, Svikis D, Montoya ID, Blaine J. Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. J Subst Abus Treat. 2004;27(1):1–8.

    Article  Google Scholar 

  43. Samet S, Waxman R, Hatzenbuehler M, Hasin DS. Assessing addiction: concepts and instruments. Addict Sci Clin Pract. 2007;4(1):19–31.

    Article  PubMed  PubMed Central  Google Scholar 

  44. ASAM’s 2019 definition of addiction. https://www.asam.org/docs/default-source/qualityscience/asam's-2019-definition-of-addiction-(1).pdf?sfvrsn=b8b64fc2_2. Published 15 Sep 2019. Accessed 15 Jan 2022.

  45. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–95.

    Article  CAS  PubMed  Google Scholar 

  46. Park SE, Mosley JE, Grogan CM, et al. Patient-centered care’s relationship with substance use disorder treatment utilization. J Subst Abus Treat. 2020;118:108125.

    Article  Google Scholar 

  47. VA DOD Clinical Practice Guideline for The Management of Substance Use Disorders. healthquality.va.gov. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf. Published August 2021. Accessed January 15, 2022.

  48. Guerrero EG. Enhancing access and retention in substance abuse treatment: the role of Medicaid payment acceptance and cultural competence. Drug Alcohol Depend. 2013;132(3):555–61. https://doi.org/10.1016/j.drugalcdep.2013.04.005.

    Article  PubMed  Google Scholar 

  49. Williams DR, Lawrence JA, Davis BA, Vu C. Understanding how discrimination can affect health. Health Serv Res. 2019;54(S2):1374–88. https://doi.org/10.1111/1475-6773.13222.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Mee-Lee D. Understanding the new ASAM criteria. NCADD Webinar. April 23, 2015. Available online: https://www.naadac.org/understanding-the-new-asam-criteria. Accessed 15 Jan 2022.

  51. Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014;65(3):301–12. https://doi.org/10.1176/appi.ps.201300242.

    Article  PubMed  Google Scholar 

  52. GAO-21-58, substance use disorder: Reliable data needed for substance abuse and prevention and treatment block grant program. https://www.gao.gov/assets/gao-21-58.pdf. Accessed 15 Jan 2022.

  53. Browne T, Priester MA, Clone S, Iachini A, DeHart D, Hock R. Barriers and facilitators to substance use treatment in the rural south: a qualitative study. J Rural Health. 2016;32(1):92–101.

    Article  PubMed  Google Scholar 

  54. Amaro H, Sanchez M, Bautista T, Cox R. Social vulnerabilities for substance use: stressors, socially toxic environments, and discrimination and racism. Neuropharmacology. 2021;188:108518. https://doi.org/10.1016/j.neuropharm.2021.108518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Raven MC, Carrier ER, Lee J, Billings JC, Marr M, Gourevitch MN. Substance use treatment barriers for patients with frequent hospital admissions. J Subst Abus Treat. 2010;38(1):22–30.

    Article  Google Scholar 

  56. van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigmatisering van pati¨enten met een verslaving en de gevolgen voor de hulpverlening: een; 2015.

    Google Scholar 

  57. Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians' treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Saitz R, Miller SC, Fiellin DA, Rosenthal RN. Recommended use of terminology in addiction medicine. J Addict Med. 2021;15(1):3–7. https://doi.org/10.1097/ADM.0000000000000673.

    Article  PubMed  Google Scholar 

  59. Des Jarlais DC. Harm reduction—a framework for incorporating science into drug policy. Am J Public Health. 1995;85:10–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006;25(6):611–24. https://doi.org/10.1080/09595230600944529.

    Article  PubMed  Google Scholar 

  61. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10(12):1187–204. https://doi.org/10.1016/j.jpain.2009.10.002.

    Article  PubMed  Google Scholar 

  62. Burton R, Henn C, Lavoie D, O’Connor R, Perkins C, Sweeney K, Greaves F, Ferguson B, Beynon C, Belloni A, et al. A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective. Lancet. 2017;389:1558–80.

    Article  PubMed  Google Scholar 

  63. Cook C, Bridge J, Stimson GV. The diffusion of harm reduction in Europe and beyond. Monographs. 2010:37–56.

    Google Scholar 

  64. Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, Wood E. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100:1449–53.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–41. https://doi.org/10.15585/mmwr.mm6448a3.

    Article  PubMed  Google Scholar 

  66. Ghertner R. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug Alcohol Depend. 2019;204:107527. https://doi.org/10.1016/j.drugalcdep.2019.06.029.

    Article  PubMed  Google Scholar 

  67. Baldaçara L, Cogo-Moreira H, Parreira BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2016;77(3):398–406.

    Article  PubMed  Google Scholar 

  68. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337–46.

    Article  PubMed  Google Scholar 

  69. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Kathleen T. Brady a double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169(8):805–12.

    Article  PubMed  Google Scholar 

  70. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140–53. https://doi.org/10.1056/NEJMoa2020214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, Delphin-Rittmon ME. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–57.

    Article  PubMed  Google Scholar 

  72. Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon MS, Kelly SM, et al. Interim methadone treatment: impact on arrests. Drug Alcohol Depend. 2009;103(3):148–54.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff. 2021;40(6):920–7. https://doi.org/10.1377/hlthaff.2020.02261.

    Article  Google Scholar 

  75. Executive summary: The selection and use of essential medicines 2021: Report of the 23rd WHO expert committee on the selection and use of essential medicines. World Health Organization. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.01. Accessed 15 Jan 2022.

  76. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–31. https://doi.org/10.1056/NEJMoa1005359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Nunes EV. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 2007;91(2–3):289–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18. https://doi.org/10.1016/S0140-6736(17)32812-X.

    Article  CAS  PubMed  Google Scholar 

  79. Tanum L, Solli KK, Latif Z, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197–205. https://doi.org/10.1001/jamapsychiatry.2017.3206.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Ajazi EM, Dasgupta N, Marshall SW, et al. Revisiting the X:BOT naltrexone clinical trial using a comprehensive survival analysis. J Addict Med. 2022;16(4):440–6. https://doi.org/10.1097/ADM.0000000000000931.

  81. Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The naloxone delivery cascade: identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021;225:108759. https://doi.org/10.1016/j.drugalcdep.2021.108759.

    Article  PubMed  Google Scholar 

  82. Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health [published online ahead of print, 2021 Jun 16]. JAMA Psychiatry. 2021;78(8):922–4. https://doi.org/10.1001/jamapsychiatry.2021.1271.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1318–25.

    Article  CAS  PubMed  Google Scholar 

  84. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27(1):113–24. https://doi.org/10.1080/13543784.2018.1417383.

    Article  CAS  PubMed  Google Scholar 

  86. National Collaborating Centre for Mental Health, National Institute for Health & Clinical Excellence. Alcohol-use disorders: the NICE guidelines on diagnosis, assessment and management of harmful drinking and alcohol dependence. The British Psychological Society and The Royal College of Psychiatrists; 2011. https://www.nice.org.uk/guidance/CG115/chapter/1-Guidance#interventions-for-alcohol-misuse. Accessed 14 Sep 2021.

    Google Scholar 

  87. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90. https://doi.org/10.1176/appi.ajp.2017.1750101.

    Article  PubMed  Google Scholar 

  88. Anton RF, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.

    Article  CAS  PubMed  Google Scholar 

  89. O’Malley SS, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163(14):1695–704.

    Article  PubMed  Google Scholar 

  90. Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive Behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e208279. https://doi.org/10.1001/jamanetworkopen.2020.8279.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Skewes MC, Hallum-Montes R, Gardner SA, Blume AW, Ricker A, FireMoon P. Partnering with native communities to develop a culturally grounded intervention for substance use disorder. Am J Community Psychol. 2019;64(1–2):72–82. https://doi.org/10.1002/ajcp.12354.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Magill M, Tonigan JS, Kiluk B, Ray L, Walthers J, Carroll K. The search for mechanisms of cognitive Behavioral therapy for alcohol or other drug use disorders: a systematic review. Behav Res Ther. 2020;131(August):103648. https://doi.org/10.1016/j.brat.2020.103648.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Glasner S, Drazdowski TK. Evidence-based Behavioral treatments for substance use disorders. In: Danovitch I, Mooney L, editors. The assessment and treatment of addiction: best practices and new frontiers. Elsevier Health Sciences; 2018.

    Google Scholar 

  94. Cohen JY, Huguet G, Cohen J, Vera L, Dardennes R. Cognitive-behavioural therapies and motivational interviewing for methamphetamine use disorders: a systematic review. J Addict Med Ther. Published online. 2017;6:1030.

    Google Scholar 

  95. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016;(5):CD005336. https://doi.org/10.1002/14651858CD005336.pub4.

  96. Magill M, Ray L, Kiluk B, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093–105. https://doi.org/10.1037/ccp0000447.

    Article  PubMed  PubMed Central  Google Scholar 

  97. McKay JR, Lynch KG, Coviello D, et al. Randomized trial of continuing care enhancements for cocaine-dependent patients following initial engagement. J Consult Clin Psychol. 2010;78(1):111–20. https://doi.org/10.1037/a0018139.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Ainscough TS, McNeill A, Strang J, Calder R, Brose LS. Contingency management interventions for non-prescribed drug use during treatment for opiate addiction: a systematic review and meta-analysis. Drug Alcohol Depend. 2017;178:318–39. https://doi.org/10.1016/j.drugalcdep.2017.05.028.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST. A review of the literature on contingency management in the treatment of substance use disorders, 2009–2014. Prev Med. 2016;92:36–46. https://doi.org/10.1016/j.ypmed.2016.08.008.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Li W, Howard MO, Garland EL, McGovern P, Lazar M. Mindfulness treatment for substance misuse: a systematic review and meta-analysis. J Subst Abus Treat. 2017;75:62–96. https://doi.org/10.1016/j.jsat.2017.01.008.

    Article  Google Scholar 

  101. Garland E, Froeliger B, Howard M. Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface. Front Psych. 2014;4:173. https://doi.org/10.3389/fpsyt.2013.00173.

    Article  Google Scholar 

  102. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012;37(1):11–24. https://doi.org/10.1016/j.addbeh.2011.09.010.

    Article  PubMed  Google Scholar 

  103. DiClemente CO, Velasquez MM. Motivational interviewing and the stages of change. In: Miller WR, Rollnick S, editors. Motivational interviewing: preparing people for change. 2nd ed. The Guilford Press; 2002. p. 201–16.

    Google Scholar 

  104. SAMHSA TIP 35: enhancing motivational interviewing for change in substance use disorder treatment. Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services; 2019. Accessed 18 Dec 2021. https://store.samhsa.gov/sites/default/files/d7/priv/tip35_final_508_compliant_-_02252020_0.pdf.

  105. Lundahl B, Burke BL. The effectiveness and applicability of motivational interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol. 2009;65(11):1232–45. https://doi.org/10.1002/jclp.20638.

    Article  PubMed  Google Scholar 

  106. Grobe JE, Goggin K, Harris KJ, Richter KP, Resnicow K, Catley D. Race moderates the effects of motivational interviewing on smoking cessation induction. Patient Educ Couns. 2020;103(2):350–8. https://doi.org/10.1016/j.pec.2019.08.023.

    Article  PubMed  Google Scholar 

  107. Beaulieu M, Tremblay J, Baudry C, Pearson J, Bertrand K. A systematic review and meta-analysis of the efficacy of the long-term treatment and support of substance use disorders. Soc Sci Med. 2021;285(September):114289. https://doi.org/10.1016/j.socscimed.2021.114289.

    Article  PubMed  Google Scholar 

  108. White W. Peer-based addiction recovery support: history, theory, practice, and scientific evaluation. Chicago, IL: Great Lakes Addiction Technology Transfer Center and Philadelphia Department of Behavioral Health and Mental Retardation Services; 2009.

    Google Scholar 

  109. Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support Services For Addictions In the United States: a systematic review. J Subst Abus Treat. 2016;63:1–9. https://doi.org/10.1016/j.jsat.2016.01.003.

    Article  Google Scholar 

  110. Jack HE, Oller D, Kelly J, Magidson JF, Wakeman SE. Addressing substance use disorder in primary care: the role, integration, and impact of recovery coaches. Subst Abus. 2018;39(3):307–14. https://doi.org/10.1080/08897077.2017.1389802.

    Article  PubMed  Google Scholar 

  111. Kelly JF, Humphreys K, Ferri M. Alcoholics anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020;2020(3):CD012880. https://doi.org/10.1002/14651858.CD012880.pub2.

    Article  PubMed Central  Google Scholar 

  112. Zemore SE, Kaskutas LA, Mericle A, Hemberg J. Comparison of 12-step groups to mutual help alternatives for AUD in a large, national study: differences in membership characteristics and group participation, cohesion, and satisfaction. J Subst Abus Treat. 2017;73:16–26. https://doi.org/10.1016/j.jsat.2016.10.004.

    Article  Google Scholar 

  113. Agbese E, Leslie DL, Manhapra A, Rosenheck R. Early discontinuation of buprenorphine therapy for opioid use disorder among privately insured adults. PS. 2020;71(8):779–88. https://doi.org/10.1176/appi.ps.201900309.

    Article  Google Scholar 

  114. Binswanger IA, Glanz JM, Faul M, et al. The association between opioid discontinuation and heroin use: a nested case-control study. Drug Alcohol Depend. 2020;217:108248. https://doi.org/10.1016/j.drugalcdep.2020.108248.

    Article  CAS  PubMed  Google Scholar 

  115. Stein BD, Sherry TB, O’Neill B, Taylor EA, Sorbero M. Rapid discontinuation of chronic, high-dose opioid treatment for pain: prevalence and associated factors. J Gen Intern Med. 2021; https://doi.org/10.1007/s11606-021-07119-3.

  116. McGeough BL, Karriker-Jaffe KJ, Zemore SE. Rates and predictors of alcoholics anonymous attendance across sexual orientations. J Subst Abus Treat. 2021;129:108400. https://doi.org/10.1016/j.jsat.2021.108400.

    Article  CAS  Google Scholar 

  117. Andraka-Christou B, Totaram R, Randall-Kosich O. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2021:1–10. https://doi.org/10.1080/08897077.2021.1944957.

  118. Zemore SE, Lui C, Mericle A, Hemberg J, Kaskutas LA. A longitudinal study of the comparative efficacy of women for sobriety, LifeRing, SMART recovery, and 12-step groups for those with AUD. J Subst Abus Treat. 2018;88:18–26. https://doi.org/10.1016/j.jsat.2018.02.004.

    Article  Google Scholar 

  119. SAMHSA.gov. SAMHSA's working definition of recovery: ten guiding principles of recovery. 2012. PEP12-RECDEF. https://store.samhsa.gov/sites/default/files/d7/priv/pep12-recdef.pdf. Accessed 21 Dec 2021.

  120. Carroll KM, Rounsaville BJ. On beyond urine: clinically useful assessment instruments in the treatment of drug dependence. Behav Res Ther. 2002;40(11):1329–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. McCollister KE, French MT, Freitas DM, Dennis ML, Scott CK, Funk RR. Cost-effectiveness analysis of recovery management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trial. Addiction. 2013;108(12):2166–74.

    Article  PubMed  Google Scholar 

  122. Scott CK, Dennis ML. Recovery management check-ups: an early re-intervention model. 2003. http://www.williamwhitepapers.com/pr/Recovery%20Management%20Checkup%20Manual%20Scott%20%26%20Dennis%202003.pdf. Accessed 21 Nov 2021.

  123. Wakeman S, Rigotti N, Chang Y, Herman G, Erwin A, Regan S, et al. Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization. J Gen Intern Med. 2019;34(6):871–7.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Haddad M, Zelenev A, Altice F. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015;92(1):193–213.

    Article  PubMed  Google Scholar 

  125. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One. 2017;12(10):e0186315.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Babor T, McRee B, Kassebaum P, Grimaldi P, Ahmed K, Bray J. Screening, brief intervention, and referral to treatment (SBIRT). Subst Abus. 2007;28(3):7–30. https://doi.org/10.1300/J465v28n03_03.

    Article  PubMed  Google Scholar 

  127. Townley C, Dorr H. Integrating substance use disorder treatment and primary care. National Academy for State Health Policy; 2017.

    Google Scholar 

  128. Tuckson RV, Edmunds M, Hodgkins ML. Telehealth. N Engl J Med. 2017;377(16):1585–92. https://doi.org/10.1056/NEJMsr1503323.

    Article  PubMed  Google Scholar 

  129. Tofighi B, Abrantes A, Stein MD. The role of technology-based interventions for substance use disorders in primary care: a review of the literature. Med Clin North Am. 2018;102(4):715–31. https://doi.org/10.1016/j.mcna.2018.02.011.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Carreiro S, Newcomb M, Leach R, Ostrowski S, Boudreaux ED, Amante D. Current reporting of usability and impact of MHealth interventions for substance use disorder: a systematic review. Drug Alcohol Depend. 2020;215(October):108201. https://doi.org/10.1016/j.drugalcdep.2020.108201.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Gonzales R, Ang A, Murphy DA, Glik DC, Douglas Anglin M. Substance use recovery outcomes among a cohort of youth participating in a mobile based texting aftercare pilot program. J Subst Abus Treat. 2014;47(1):20–6. https://doi.org/10.1016/j.jsat.2014.01.010.

    Article  Google Scholar 

  132. Ondersma SJ, Ellis JD, Resko SM, Grekin E. Technology-delivered interventions for substance use among adolescents. Pediatr Clin N Am. 2019;66(6):1203–15. https://doi.org/10.1016/j.pcl.2019.08.009.

    Article  Google Scholar 

  133. McDonnell A, MacNeill C, Chapman B, Gilbertson N, Reinhardt M, Carreiro S. Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response. J Subst Abus Treat. 2021;124:108226. https://doi.org/10.1016/j.jsat.2020.108226.

    Article  CAS  Google Scholar 

  134. Lin L(A), Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abus Treat. 2019;101(June):38–49. https://doi.org/10.1016/j.jsat.2019.03.007.

    Article  Google Scholar 

  135. Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273–88. https://doi.org/10.1080/00952990.2019.1694536.

    Article  PubMed  Google Scholar 

  136. Rodriguez JA, Betancourt JR, Sequist TD, Ganguli I. Differences in the use of telephone and video telemedicine visits during the COVID-19 pandemic. Am J Manag Care. 2021;27(1):21–6. https://doi.org/10.37765/ajmc.2021.88573.

    Article  PubMed  Google Scholar 

  137. Text—S.524—114th Congress (2015–2016): comprehensive addiction and recovery act of 2016. Congress.gov, Library of Congress; 22 July 2016, https://www.congress.gov/bill/114th-congress/senate-bill/524/text.

  138. Practice guidelines for the administration of buprenorphine for treating opioid use disorder, 21 U.S.C. 823(g)(2)(H)(i)(II). (2021). https://www.govinfo.gov/content/pkg/FR-2021-04-28/pdf/2021-08961.pdf.

  139. https://www.pewtrusts.org/en/research-and-analysis/articles/2022/12/30/president-signs-bipartisan-measure-toimprove-addiction-treatment.

  140. Center for Behavioral Health Statistics and Quality. Results from the 2015 National Survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.

    Google Scholar 

  141. Lipari RN, Hedden SL, Hughes A. Substance use and mental health estimates from the 2013 National Survey on drug use and health: overview of findings. 2014 Sep 4. In: The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2013. https://www.ncbi.nlm.nih.gov/books/NBK385055/.

  142. Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156(6):607–14. https://doi.org/10.1001/archpedi.156.6.607.

    Article  PubMed  Google Scholar 

  143. Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14:70. https://doi.org/10.1186/s12954-017-0196-4.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357–68. https://doi.org/10.1056/NEJMra1604339.

    Article  PubMed  Google Scholar 

  145. Agency for Healthcare Research and Quality. Pharmacotherapy for adults with alcohol-use disorders in outpatient settings; executive summary; 2014. http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1907 Accessed 18 Jan 2017.

  146. About the ASAM criteria [Internet]. American Society of Addiction Medicine. [cited 2022 Mar 7]. https://www.asam.org/asam-criteria/about-the-asam-criteria

  147. Bronfenbrenner U. The ecology of human development: experiments by nature and design. Harvard University Press; 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Michael H. Baca-Atlas & Kelly Bossenbroek Fedoriw

  2. University of North Carolina at Chapel Hill School of Social Work, Chapel Hill, NC, USA

    Stefani N. Baca-Atlas

Authors
  1. Michael H. Baca-Atlas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefani N. Baca-Atlas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly Bossenbroek Fedoriw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael H. Baca-Atlas .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of North Carolina, CHAPEL HILL, NC, USA

    Timothy P. Daaleman

  2. Department of Family Medicine, University of North Carolina, CHAPEL HILL, NC, USA

    Margaret R. Helton

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Baca-Atlas, M.H., Baca-Atlas, S.N., Fedoriw, K.B. (2023). Alcohol and Drug Use Disorders. In: Daaleman, T.P., Helton, M.R. (eds) Chronic Illness Care. Springer, Cham. https://doi.org/10.1007/978-3-031-29171-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-29171-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-29170-8

  • Online ISBN: 978-3-031-29171-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation